Qiagen N.V. (QGEN) Releases Earnings Results
Qiagen N.V. (NASDAQ:QGEN) posted its quarterly earnings data on Thursday, July 27th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.02, MarketWatch Earnings reports. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The firm had revenue of $349 million during the quarter, compared to analysts’ expectations of $353.09 million. During the same period in the prior year, the business earned $0.24 EPS. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Qiagen N.V. updated its FY17 guidance to $1.25-1.27 EPS.
Qiagen N.V. (NASDAQ:QGEN) opened at 32.11 on Monday. Qiagen N.V. has a 12-month low of $24.86 and a 12-month high of $35.26. The stock’s 50 day moving average price is $33.97 and its 200 day moving average price is $31.03. The company has a market capitalization of $7.33 billion, a PE ratio of 98.20 and a beta of 1.14.
A number of equities research analysts have recently weighed in on QGEN shares. Deutsche Bank AG reissued a “buy” rating on shares of Qiagen N.V. in a research note on Tuesday, May 2nd. Commerzbank Ag reaffirmed a “buy” rating on shares of Qiagen N.V. in a research report on Wednesday, May 3rd. Barclays PLC reaffirmed a “buy” rating and set a $33.00 price target on shares of Qiagen N.V. in a research report on Friday, May 5th. TheStreet lowered Qiagen N.V. from a “b” rating to a “c+” rating in a research report on Thursday, July 27th. Finally, Independent Research GmbH raised Qiagen N.V. from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $33.19.
COPYRIGHT VIOLATION WARNING: “Qiagen N.V. (QGEN) Releases Earnings Results” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/07/qiagen-n-v-qgen-announces-earnings-results-updated.html.
Large investors have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in shares of Qiagen N.V. by 8,793.4% in the first quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock worth $227,114,000 after buying an additional 7,751,485 shares during the period. Johnston Asset Management LLC raised its stake in Qiagen N.V. by 1.1% in the second quarter. Johnston Asset Management LLC now owns 3,612,479 shares of the company’s stock valued at $121,126,000 after buying an additional 39,145 shares during the last quarter. Frontier Capital Management Co. LLC raised its stake in Qiagen N.V. by 3.6% in the second quarter. Frontier Capital Management Co. LLC now owns 2,536,075 shares of the company’s stock valued at $85,035,000 after buying an additional 87,069 shares during the last quarter. Legal & General Group Plc raised its stake in Qiagen N.V. by 2,651.3% in the first quarter. Legal & General Group Plc now owns 1,896,813 shares of the company’s stock valued at $16,690,000 after buying an additional 1,827,871 shares during the last quarter. Finally, Edmond DE Rothschild Holding S.A. acquired a new stake in Qiagen N.V. during the first quarter valued at approximately $46,480,000. 60.45% of the stock is currently owned by hedge funds and other institutional investors.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Stock Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related stocks with our FREE daily email newsletter.